Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Announces FY2005 Results; On Track for Bacterial Analysis System

NEW YORK, Nov. 2 (GenomeWeb News) - Accelr8 Technology had increased revenues in its fiscal year 2005 results, which ended July 31, the company said this morning.


The Denver-based company reported sales of its OptiChem microarraying slides had nearly tripled to $336,610 for the fiscal year. The slides accounted for 67% of the company's total revenue. For the fourth quarter, the company's total revenues increased to approximately $118,000 from $33,100 the previous year.


Fourth quarter R&D costs were approximately $485,000, a significant increase from $146,000 during the same quarter last year. The company attributed the increase to continued work on its BACcelr8r rapid bacterial analysis system.


"We've installed our first in-house research version of the BACcerlr8r," said David Howson, Accelr8's president in a statement. "We also started the engineering design on the next generation of the research platform."


Accelr8's fiscal year net losses totaled $2 million, or $.21 per share, compared to a loss of $909,421 or $.09 per share the previous year.


As of July 31, Accelr8 had $5.6 million in cash and cash equivalents.



The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.